Alaunos Therapeutics, Inc. carries no debt; cash flow comfortably covers obligations.

Alaunos Therapeutics, Inc.'s free cash flow has increased -40.31% from $-4.97M last year to $-2.97M, signaling increasing performance

Alaunos Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Alaunos Therapeutics, Inc. has insufficient data to evaluate this check.

Alaunos Therapeutics, Inc. has a net cash position, so leverage is healthy.

Alaunos Therapeutics, Inc. carries no debt; interest obligations are fully covered.

Alaunos Therapeutics, Inc.'s profit margin has decreased (192.73%) in the last year from -46.79K% to -136.97K%, signaling decreasing performance

Alaunos Therapeutics, Inc.'s short-term assets of $1.99M exceed its short-term liabilities of $813.00K

Alaunos Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Alaunos Therapeutics, Inc.'s return on equity of -165.94%, is lower than 15.00%, indicating bad performance

Alaunos Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Alaunos Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Alaunos Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Alaunos Therapeutics, Inc. has negative free cash flow, indicating cash burn

Alaunos Therapeutics, Inc.'s yearly earnings has increased -10.75% since last year from $-4.68M to $-4.18M, signaling increasing performance

Alaunos Therapeutics, Inc.'s yearly revenue has decreased 50.00% since last year from $10.00K to $5.00K, signaling decreasing performance

ROIC -321.82% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Alaunos Therapeutics, Inc.'s 3-year revenue CAGR of -88.04% is negative, indicating declining revenue over the past 3 years

Alaunos Therapeutics, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Alaunos Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Alaunos Therapeutics, Inc. has insufficient data to evaluate this check.

Alaunos Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Alaunos Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Alaunos Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Alaunos Therapeutics, Inc. has insufficient data to evaluate this check.

Alaunos Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Alaunos Therapeutics, Inc. has a price-to-book ratio of 3.00x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Alaunos Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue